Consorci Sanitari De Terrassa

The department is advancing treatment for a range of cancers, including breast, cervical, endometrial, colorectal, lung, and prostate malignancies, by testing new therapeutic combinations and maintenance strategies.

• Adjuvant therapy evaluation for early‑stage breast cancer
• Sequencing of biologic agents with chemotherapy in metastatic colorectal cancer
• Combination immunotherapy for resectable non‑small cell lung cancer
• Maintenance approaches in advanced endometrial cancer
• Risk‑adapted treatment for high‑risk localized prostate cancer

Consorci Sanitari De Terrassa supports 24 active trials with 25 investigators, highlighting its role in oncology research across Europe.

Research aims to improve outcomes for patients with cardiovascular disease by evaluating novel lipid‑lowering agents and anti‑inflammatory therapies.

• Lipoprotein(a) reduction and cardiovascular event prevention
• Assessment of oral versus parenteral antibiotic strategies for infective endocarditis
• Evaluation of aspirin discontinuation protocols for preeclampsia prevention

The site’s multidisciplinary team contributes to advancing heart health while collaborating with national cardiovascular networks.

Studies focus on improving management of respiratory conditions, particularly lung cancer and related surgical outcomes.

• Post‑operative infection prevention in total joint replacement
• Evaluation of fibrin‑based adhesives to reduce esophagojejunal anastomosis dehiscence after gastrectomy
• Combination therapy trials for resectable non‑small cell lung cancer

These trials integrate surgical expertise with medical oncology to enhance patient recovery and survival.

The unit investigates innovative immunomodulatory approaches for immune‑mediated disorders, including allergic diseases and autoimmune neuro‑psychiatric conditions.

• Allergen immunotherapy for house‑dust mite‑related rhinitis and asthma
• Subcutaneous immunotherapy with Cup a 1 protein for allergic rhinoconjunctivitis
• Complement component 5 inhibition for geographic atrophy
• KarXT combination therapy for agitation in Alzheimer’s disease

By targeting key immune pathways, the site contributes to safer and more effective treatments for chronic allergic and neuro‑inflammatory conditions.

Clinical work seeks to lower infection risk and improve healing in musculoskeletal surgery, especially joint replacement procedures.

• Comparison of antiseptic irrigation solutions versus saline in total hip and knee arthroplasty
• Evaluation of local vancomycin application to prevent prosthetic joint infection
• Outpatient oral antibiotic therapy as an alternative to parenteral treatment for surgical infections

These investigations aim to reduce postoperative complications and shorten hospital stays for orthopedic patients.

Trials address acute and chronic conditions of the gastrointestinal tract, testing fluid management and surgical adjuncts.

• Lactated Ringer’s solution versus normal saline for acute pancreatitis resuscitation
• Fibrin‑based adhesive use to prevent esophagojejunal anastomosis leaks after total gastrectomy
• Sequencing of chemotherapy and targeted agents in metastatic colorectal cancer

The research combines critical care and surgical expertise to enhance recovery and long‑term outcomes.

Focused studies aim to slow progression of age‑related macular degeneration and its advanced form, geographic atrophy.

• Complement inhibition therapy to reduce lesion growth in geographic atrophy
• Evaluation of novel subcutaneous agents for macular disease management

By targeting underlying complement pathways, the site seeks to preserve vision in affected patients.

Research explores therapies for neurological disorders, including migraine and Alzheimer’s‑related agitation.

• Botulinum toxin (Xeomin) injections for chronic migraine prevention
• Xeomin treatment for episodic migraine reduction
• KarXT plus KarX‑EC combination for agitation in Alzheimer’s disease

These trials aim to improve quality of life for patients with debilitating headache and neuro‑psychiatric symptoms.

The department evaluates novel pharmacologic options for psychiatric conditions, focusing on agitation associated with dementia.

• KarXT plus KarX‑EC versus placebo for agitation in Alzheimer’s disease

The study seeks to provide safer, more effective management of behavioral symptoms in elderly patients.

Clinical investigations target resistant bacterial infections, especially urinary and prosthetic infections.

• Oral fosfomycin‑tromethamol for multidrug‑resistant Escherichia coli prostatitis
• Outpatient oral antibiotic therapy versus parenteral treatment for infective endocarditis

By exploring oral alternatives, the trials aim to reduce hospitalization time while maintaining therapeutic efficacy.

Studies evaluate allergen‑specific immunotherapies and symptom‑relief strategies for allergic rhinitis with or without asthma.

• Subcutaneous immunotherapy with house‑dust mite extracts
• Grass and olive pollen immunotherapy using mobile‑app symptom tracking
• Cup a 1 protein immunotherapy for Cupressaceae pollen allergy
• Comparison of oral antihistamine regimens for moderate‑to‑severe rhinitis

These projects aim to reduce symptom burden and improve daily functioning for allergy sufferers.